07:00 , Oct 5, 2009 |  BioCentury  |  Emerging Company Profile

Quantum Immunologics: Going to School

Quantum Immunologics Inc. Tampa, Fla. Technology: Autologous dendritic cell immunotherapy containing oncofetal antigen/immature laminin receptor protein (OFA/iLRP) Disease focus: Cancer Clinical status: Phase I/II Founded: 2008 by Charles Broes University collaborators: University of South Alabama...
07:00 , Oct 5, 2009 |  BioCentury  |  Emerging Company Profile

Quantum Immunologics: Going to School

Quantum Immunologics Inc. is developing an autologous dendritic cell therapy that it says applies lessons learned from Dendreon Corp. 's path through the clinic with Provenge sipuleucel-T. Where Quantum says it is differentiated from other...